Article Details

Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients

Retrieved on: 2024-10-24 19:12:37

Tags for this article:

Click the tags to see associated articles and topics

Clarametyx Biosciences Initiates Phase 2a Trial for CMTX-101 in Cystic Fibrosis Patients. View article details on hiswai:

Excerpt

Our lead effort is CMTX-101, which is a therapeutic monoclonal antibody. This antibody targets the DNA b2 binding protein, which is a bacterial-only ...

Article found on: www.contagionlive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up